MacMahon B, Cole P, Brown J B, Paffenbarger R, Trichopoulos D, Yen S
J Natl Cancer Inst. 1983 Feb;70(2):247-50.
Urine specimens from 94 premenopausal women with breast cancer and from 70 control women have been compared with respect to concentration of the three major estrogen fractions and to frequency of ovulation as assessed by urine pregnanediol. The probability of anovulation (0.14 in the breast cancer patients and 0.09 among the controls) was not significantly higher among the women with breast cancer (P approximately 0.30). However, there was a positive association between urine estrogen concentration and breast cancer risk. The association was statistically significant (P less than 0.05) for each of the three estrogens measured and in both the follicular and the luteal phases of the menstrual cycle; the relative risk increased from 1 in the referent category (less than 5 micrograms estrogen/g creatinine) to about 3 in the highest category (greater than or equal to 15 micrograms estrogen/g creatinine). The association between urine estrogens and breast cancer risk was consistently stronger when the comparison was restricted to specimens collected in menstrual cycles during which ovulation occurred.
对94名绝经前乳腺癌女性和70名对照女性的尿液样本进行了比较,比较内容包括三种主要雌激素组分的浓度以及通过尿孕二醇评估的排卵频率。乳腺癌患者的无排卵概率(0.14)和对照组的无排卵概率(0.09)相比,在乳腺癌女性中并无显著升高(P约为0.30)。然而,尿雌激素浓度与乳腺癌风险之间存在正相关。对于所测量的三种雌激素中的每一种,以及在月经周期的卵泡期和黄体期,这种相关性均具有统计学意义(P<0.05);相对风险从参照类别(雌激素<5微克/克肌酐)中的1增加到最高类别(雌激素≥15微克/克肌酐)中的约3。当比较仅限于在发生排卵的月经周期中收集的样本时,尿雌激素与乳腺癌风险之间的相关性始终更强。